Elsevier

Peptides

Volume 21, Issue 12, December 2000, Pages 1903-1940
Peptides

Review Article
The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins

https://doi.org/10.1016/S0196-9781(00)00348-XGet rights and content

Abstract

The purpose of the present review is to describe the place of endogenous kinins, mainly bradykinin (BK) and des-Arg9-BK in the kallikrein-kininogen-kinin system, to review and compare the different analytical methods reported for the assessment of endogenous kinins, to explain the difficulties and the pitfalls for their quantifications in biologic samples and finally to see how the results obtained by these methods could complement and extend the pharmacological evidence of their pathophysiological role.

Introduction

The interest for the kallikrein-kininogen-kinin system originates in the early experiments of Abelous and Bardier [1] who observed almost one century ago that the injection of an alcohol-insoluble fraction of human urine caused hypotension when injected i.v. into the anesthetized dog. Later, Frey [121] confirmed this first observation by i.v. injection of human or dog urine into dogs. The active compound responsible for the hypotensive effect was attributed to a specific substance named “F-substance” which was isolated from human urine [122], [194]. Kraut et al. [195] found that high concentrations of F-substance are present in the pancreas and it was thought that the pancreas was the main site of its synthesis. F-substance was then called “kallikrein”. Since that time glandular and plasma kallikrein have been shown to be specific activators of kininogens, kinins being responsible for the measured hypotensive effects.

The kallikreins, their precursors plasma prekallikrein and tissue prokallikrein, and kininogens have been isolated, characterized at the molecular and gene levels. Their tissue distribution and the mechanisms underlying the regulation of their expression have also been studied. Their behavior and their potential role in different pathologies have also been defined. The results of these investigations have recently been extensively reviewed [34], [74], [181], [234].

In 1949, Rocha e Silva et al. [318] have isolated bradykinin (BK) released from kininogens by the venom of Bothrops jararaca. Since that time, other kinins have also been characterized in different milieus and animal species. The nature of the enzymes responsible for their metabolism has been elucidated. The term “kininase” was then coined to define these inactivating enzymes. The mechanism of inactivation of kinins in plasma began with the characterization of carboxypeptidase N (kininase I) that releases the Arg residue from the carboxy-terminal end of BK, and kallidin (KD; Lys-BK) [111]. Afterwards, Yang and Erdös [414] isolated an enzyme (kininase II) that liberated the Phe8-Arg9 dipeptide of BK. Kininase II was later proved to be identical with the angiotensin I-converting enzyme (ACE) [415]. Additional kinin peptidases were thereafter identified and characterized such as carboxypeptidase M, neutral endopeptidase 24.11 and aminopeptidase P. The biologic effects of kinins are mediated by specific receptors. Kinin receptors have been classified according to the relative potencies of series of agonists and antagonists as proposed by Regoli and Barabé [309]. They stated that the B1-type of receptors for kinins are selectively sensitive to kinins lacking the carboxy-terminal Arg residue like des-Arg9-BK and Lys-des-Arg9-BK (des-Arg10-KD). On the other hand, the B2-type of receptors is optimally stimulated by the full sequence of BK, and Lys-BK (KD). The pharmacological characteristics, the nature of the second messengers and the regulation of these receptors have been extensively studied and the different results have been recently discussed by Hall [139] for the B2 receptor and by Marceau [228], [231] for the B1 receptor.

The synthesis of specific antagonists for both B1 and B2 receptors has brought some pharmacological evidence for the participation of BK and/or des-Arg9-BK in different pathophysiological processes, and also in their role in the beneficial cardiovascular effects of ACE inhibitors.

As for other peptides, different immunologic methods have been developed for the assessment of endogenous kinins, mainly BK. However, only a very low proportion of published papers dealing with kinins include the quantification of endogenous kinins. Moreover, and contrarily to other vasoactive peptides, the methods described in the literature for the measurement of kinins were not successfully developed commercially. The reasons for this lack of success appear to be the result of the nature of the peptides and also analytical difficulties linked to the BK, and des-Arg9-BK methodological pitfalls, lability of kinins, and autocrine and paracrine nature rather than endocrine activity.

The purpose of the present review is to describe the place of endogenous kinins, mainly BK, and des-Arg9-BK in the kallikrein-kininogen-kinin system, to review and compare the different methods reported for the assessment of endogenous kinins, to explain the difficulties and the pitfalls for their quantifications in biologic samples and finally to see how the results obtained by these methods could complement and extend the pharmacological evidence of their pathophysiological role.

Section snippets

Kallikreins

Plasma and tissue (glandular) kallikreins are the two most potent kininogenases known; however, they differ completely in their biochemical, immunologic and functional characteristics [34].

Analytical methods to measure endogenous kinins

In order to determine endogenous kinin levels in biologic fluids and tissues, different immunologic methods, mainly radioimmunoassays, have been developed. Due to the nature of these peptides and their lability to enzymes, sensitive and accurate measurement of endogenous kinins, B1 and B2 agonists, remains an important challenge.

Endogenous kinins in biologic milieus

Immunologic methods have been applied to the quantification of endogenous kinins in various biologic milieus. In this section, we will focus on plasma and urinary kinin measurements. The results obtained for other milieus will be described in the section devoted to the pathophysiological aspects.

Endogenous kinins as proinflammatory peptides

Considerable pharmacological evidence supports a role for BK, and des-Arg9-BK as endogenous mediators of inflammation. In fact, they induce an inflammatory response when injected exogenously into tissues. Their levels are elevated and related to the intensity of the inflammatory response. A specific inhibitor of their production inhibits dose-dependently both the local inflammatory response and the local concentration of the mediators. Alternatively, specific kinin antagonists of B1 and B2

Endogenous kinins as antihypertensive and cardioprotective peptides

Different experimental evidence points to a role of kinins, mainly BK, in the cardioprotective effects of ACE inhibitors. This evidence is mainly of pharmacological nature and has been obtained in hypertension, myocardial infarction, left ventricular hypertrophy and diabetes. These indirect findings which are sometimes conflicting (e.g. left ventricular hypertrophy) or incomplete, and have been recently extensively reviewed [214]. In this last section, we will focus on the various

Conclusion

The quantitative assessment of endogenous BK, and des-Arg9-BK has not only supported the pharmacological experimental results based on both B2 and B1 ligands, but has also shed new light on their pathophysiological roles.

In plasma, the reported concentrations of BK, and des-Arg9-BK are not readily comparable due to the fact that some of the immunologic methods have been poorly validated. These methods are often based on a single publication, without any further application. Moreover, other

Acknowledgements

C. Blais, Jr. is the recipient of a scholarship from the Fonds de la recherche en santé du Québec (FRSQ).

References (425)

  • K.E. Bernstein et al.

    Mouse angiotensin-converting enzyme is a protein composed of two homologous domains

    J Biol Chem

    (1989)
  • C. Blais et al.

    Absence of effect of a chronic angiotensin II type 1 receptor blockade on endogenous kinin concentrations in the carrageenan-induced paw edema model in the rat

    Peptides

    (1999)
  • C. Blais et al.

    Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysisrole of ACE, and aminopeptidase P

    Peptides

    (1999)
  • C. Blais et al.

    Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema

    Immunopharmacology

    (1999)
  • P.E. Bock et al.

    Protein-protein interactions in contact activation of blood coagulation. Binding of high molecular weight kininogen and the 5-(iodoacetamido)fluorescein-labeled kininogen light chain to prekallikrein, kallikrein, and the separated kallikrein heavy and light chains

    J Biol Chem

    (1985)
  • J.A. Borkowski et al.

    Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons

    J Biol Chem

    (1995)
  • D.J. Campbell et al.

    Strategies for measurement of angiotensin and bradykinin peptides and their metabolites in central nervous system and other tissues

    Methods Neurosci

    (1995)
  • T. Cole et al.

    Major acute phase α1-protein of the rat is homologous to bovine kininogen and contains the sequence for bradykininits synthesis is regulated at the mRNA level

    FEBS Lett

    (1985)
  • R.W. Colman et al.

    Contact systema vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes

    Blood

    (1997)
  • G. Czirjak et al.

    Cloning and functional expression of the cytoplasmic form of rat aminopeptidase P

    Biochim Biophys Acta

    (1999)
  • A.J. Davis et al.

    Induction of B1 receptors in vivo in a model of persistent inflammatory mechanical hyperalgesia in the rat

    Neuropharmacology

    (1994)
  • A. Décarie et al.

    Effects of captopril and icatibant on bradykinin (BK) and des[Arg9]BK in carrageenan-induced edema

    Peptides

    (1996)
  • A. Décarie et al.

    Development of digoxigenin-labeled peptideapplication to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues

    Peptides

    (1994)
  • P.A. Deddish et al.

    Carboxypeptidase M in Madin-Darby canine kidney cells. Evidence that carboxypeptidase M has a phosphatidylinositol glycan anchor

    J Biol Chem

    (1990)
  • R.A. DeLa Cadena et al.

    Structure and functions of human kininogens

    Trends Pharmacol Sci

    (1991)
  • W.F.C. de Weerd et al.

    Bradykinin sequesters B2 bradykinin receptors and the receptor-coupled Gα subunits Gαq and Gαi in caveolae in DDT1 MF-2 smooth muscle cells

    J Biol Chem

    (1997)
  • J.E. Abelous et al.

    Les substances hypotensives de l’urine humaine normale

    C R Soc Biol (Paris)

    (1909)
  • A. Adam et al.

    Human kininogens of low and high molecular massquantification by radioimmunoassay and determination of reference values

    Clin Chem

    (1985)
  • Adam A, Blais C, Marceau F. The contribution of angiotensin-converting enzyme (ACE) to the metabolism of kinins...
  • K.G. Alberti

    The clinical implications of impaired glucose tolerance

    Diabet Med

    (1996)
  • H.A. Al-Haboubi et al.

    A synovial amidase acting on tissue kallikrein-selective substrate in clinical and experimental arthritis

    Adv Exp Med Biol

    (1986)
  • F. Alhenc-Gelas et al.

    Genetic and physiological aspects of angiotensin I-converting enzyme

  • S.O. Andrade et al.

    Purification of bradykinin by ion-exchange chromatography

    Biochem J

    (1956)
  • I. Aramori et al.

    Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657

    Mol Pharmacol

    (1997)
  • R. Audet et al.

    Cardiovascular effects of Sar-[d-Phe8]des-Arg9-bradykinin, a metabolically protected agonist of B1 receptor for kinins, in the anesthetized rabbit pretreated with a subletal dose of bacterial lipopolysaccharide

    J Pharmacol Exp Ther

    (1997)
  • D.R. Bachvarov et al.

    Characterization of two polymorphic sites in the human kinin B1 receptor genealtered frequency of an allele in patients with a history of end stage renal failure

    J Am Soc Nephrol

    (1998)
  • D.R. Bachvarov et al.

    Cloning and pharmacological characterization of the rabbit bradykinin B2 receptor

    J Pharmacol Exp Ther

    (1995)
  • Y.S. Bakhle

    Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung

    Nature

    (1968)
  • G. Bao et al.

    Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril

    Hypertension

    (1992)
  • G. Bao et al.

    Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models

    J Cardiovasc Pharmacol

    (1992)
  • P.E. Barker et al.

    The common acute lymphoblastic leukemia antigen gene maps to chromosomal region 3 (q21–q27)

    J Immunol

    (1989)
  • A. Barlas et al.

    Increased plasma level of T-kininogen in rats treated with Freund’s adjuvant

    Adv Exp Med Biol

    (1986)
  • S. Bastian et al.

    Stable expression of human kinin B1 receptor in 293 cellspharmacological and functional characterization

    Br J Pharmacol

    (1997)
  • J.M. Bathon et al.

    Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptides

    J Clin Invest

    (1992)
  • C.R. Baumgarten et al.

    Ramiprilat increases bradykinin outflow from isolated hearts of rat

    Br J Pharmacol

    (1993)
  • G. Beaubien et al.

    Gene structure and chromosomal localization of plasma kallikrein

    Biochemistry

    (1991)
  • A. Benetos et al.

    Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist

    Hypertension

    (1986)
  • T. Benzing et al.

    Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells

    Circulation

    (1999)
  • Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev...
  • C. Blais et al.

    Increase in blood bradykinin concentration after eccentric weight-training exercise in men

    J Appl Physiol

    (1999)
  • Cited by (122)

    • Bradykinin receptors: Agonists, antagonists, expression, signaling, and adaptation to sustained stimulation

      2020, International Immunopharmacology
      Citation Excerpt :

      The formation of kinins and their degradation by interesting peptidases, such as angiotensin-converting enzyme, will not be covered in the present text. The arduous endeavor of the analytic biochemistry of BK-related peptides is outlined elsewhere [3]. We rather propose an excursion into the pharmacology of kinins, the first author having been a spectator and an actor in the field for the past 40 years.

    • Analysis of the intersexual variation in Thalassophryne maculosa fish venoms

      2016, Toxicon
      Citation Excerpt :

      In animal models of inflammation using T. nattereri venom it is observed local plasma protein efflux and edema formation. These alterations are due, at least in part, to activation of the tissue kallykrein–kininogen–kinin system leading to local generation of kinins (Marangoni et al., 1993; Blais et al., 2000) being the major mechanism involved in T. nattereri venom-induced oedema and nociception (Lopes-Ferreira et al., 1998). In this study we have demonstrated for the first time the leukocyte recruitment in a footpad of mice injured with T. maculosa venom.

    View all citing articles on Scopus
    View full text